Logo image of TRT

TRIO-TECH INTERNATIONAL (TRT) Stock Fundamental Analysis

USA - NYSEARCA:TRT - US8967122057 - Common Stock

5.51 USD
+0.03 (+0.55%)
Last: 9/19/2025, 6:40:00 PM
Fundamental Rating

4

Taking everything into account, TRT scores 4 out of 10 in our fundamental rating. TRT was compared to 112 industry peers in the Semiconductors & Semiconductor Equipment industry. TRT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. TRT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

TRT had negative earnings in the past year.
TRT had a positive operating cash flow in the past year.
TRT had positive earnings in 4 of the past 5 years.
In the past 5 years TRT always reported a positive cash flow from operatings.
TRT Yearly Net Income VS EBIT VS OCF VS FCFTRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M 4M 6M 8M

1.2 Ratios

The Return On Assets of TRT (0.05%) is comparable to the rest of the industry.
With a Return On Equity value of 0.06%, TRT perfoms like the industry average, outperforming 50.89% of the companies in the same industry.
TRT's Return On Invested Capital of 0.04% is in line compared to the rest of the industry. TRT outperforms 47.32% of its industry peers.
The Average Return On Invested Capital over the past 3 years for TRT is significantly below the industry average of 10.87%.
The 3 year average ROIC (4.20%) for TRT is well above the current ROIC(0.04%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.05%
ROE 0.06%
ROIC 0.04%
ROA(3y)3.88%
ROA(5y)2.51%
ROE(3y)5.73%
ROE(5y)3.71%
ROIC(3y)4.2%
ROIC(5y)N/A
TRT Yearly ROA, ROE, ROICTRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 -2 4 6 8

1.3 Margins

With a Profit Margin value of 0.05%, TRT perfoms like the industry average, outperforming 51.79% of the companies in the same industry.
TRT's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 0.05%, TRT is in line with its industry, outperforming 47.32% of the companies in the same industry.
TRT's Operating Margin has improved in the last couple of years.
The Gross Margin of TRT (25.88%) is worse than 76.79% of its industry peers.
In the last couple of years the Gross Margin of TRT has grown nicely.
Industry RankSector Rank
OM 0.05%
PM (TTM) 0.05%
GM 25.88%
OM growth 3YN/A
OM growth 5Y6.23%
PM growth 3YN/A
PM growth 5Y-8.9%
GM growth 3Y2.49%
GM growth 5Y2.07%
TRT Yearly Profit, Operating, Gross MarginsTRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20 25

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TRT is destroying value.
The number of shares outstanding for TRT has been increased compared to 1 year ago.
The number of shares outstanding for TRT has been increased compared to 5 years ago.
TRT has a better debt/assets ratio than last year.
TRT Yearly Shares OutstandingTRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
TRT Yearly Total Debt VS Total AssetsTRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

TRT has an Altman-Z score of 3.89. This indicates that TRT is financially healthy and has little risk of bankruptcy at the moment.
With a Altman-Z score value of 3.89, TRT perfoms like the industry average, outperforming 52.68% of the companies in the same industry.
TRT has a debt to FCF ratio of 2.30. This is a good value and a sign of high solvency as TRT would need 2.30 years to pay back of all of its debts.
TRT's Debt to FCF ratio of 2.30 is fine compared to the rest of the industry. TRT outperforms 67.86% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that TRT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, TRT is in the better half of the industry, outperforming 66.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 2.3
Altman-Z 3.89
ROIC/WACC0
WACC11.32%
TRT Yearly LT Debt VS Equity VS FCFTRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 4.89 indicates that TRT has no problem at all paying its short term obligations.
The Current ratio of TRT (4.89) is better than 69.64% of its industry peers.
TRT has a Quick Ratio of 4.54. This indicates that TRT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.54, TRT is in the better half of the industry, outperforming 76.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.89
Quick Ratio 4.54
TRT Yearly Current Assets VS Current LiabilitesTRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

1

3. Growth

3.1 Past

TRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.45%.
The Earnings Per Share has been decreasing by -9.82% on average over the past years.
Looking at the last year, TRT shows a very negative growth in Revenue. The Revenue has decreased by -14.65% in the last year.
Measured over the past years, TRT shows a small growth in Revenue. The Revenue has been growing by 1.54% on average per year.
EPS 1Y (TTM)-100.45%
EPS 3YN/A
EPS 5Y-9.82%
EPS Q2Q%-804.82%
Revenue 1Y (TTM)-14.65%
Revenue growth 3Y9.24%
Revenue growth 5Y1.54%
Sales Q2Q%-29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRT Yearly Revenue VS EstimatesTRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

1

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
TRT Price Earnings VS Forward Price EarningsTRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

TRT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TRT is cheaper than 100.00% of the companies in the same industry.
TRT's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 70.68
EV/EBITDA 0.08
TRT Per share dataTRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for TRT!.
Industry RankSector Rank
Dividend Yield N/A

TRIO-TECH INTERNATIONAL

NYSEARCA:TRT (9/19/2025, 6:40:00 PM)

5.51

+0.03 (+0.55%)

Chartmill FA Rating
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)05-19 2025-05-19
Earnings (Next)09-22 2025-09-22
Inst Owners16.54%
Inst Owner Change46.77%
Ins Owners25.82%
Ins Owner Change0%
Market Cap23.75M
Analysts0
Price TargetN/A
Short Float %0.12%
Short Ratio0.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.67
P/FCF 70.68
P/OCF 21.99
P/B 0.73
P/tB 0.73
EV/EBITDA 0.08
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY1.41%
OCF(TTM)0.25
OCFY4.55%
SpS8.25
BVpS7.5
TBVpS7.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.05%
ROE 0.06%
ROCE 0.05%
ROIC 0.04%
ROICexc 0.08%
ROICexgc 0.08%
OM 0.05%
PM (TTM) 0.05%
GM 25.88%
FCFM 0.95%
ROA(3y)3.88%
ROA(5y)2.51%
ROE(3y)5.73%
ROE(5y)3.71%
ROIC(3y)4.2%
ROIC(5y)N/A
ROICexc(3y)7.45%
ROICexc(5y)N/A
ROICexgc(3y)7.45%
ROICexgc(5y)N/A
ROCE(3y)5.9%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y11.52%
ROICexc growth 3YN/A
ROICexc growth 5Y11.52%
OM growth 3YN/A
OM growth 5Y6.23%
PM growth 3YN/A
PM growth 5Y-8.9%
GM growth 3Y2.49%
GM growth 5Y2.07%
F-Score6
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 2.3
Debt/EBITDA 0.17
Cap/Depr 26.75%
Cap/Sales 2.09%
Interest Coverage 0.25
Cash Conversion 38.59%
Profit Quality 1768.42%
Current Ratio 4.89
Quick Ratio 4.54
Altman-Z 3.89
F-Score6
WACC11.32%
ROIC/WACC0
Cap/Depr(3y)49.65%
Cap/Depr(5y)43.62%
Cap/Sales(3y)5.01%
Cap/Sales(5y)4.28%
Profit Quality(3y)151.17%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.45%
EPS 3YN/A
EPS 5Y-9.82%
EPS Q2Q%-804.82%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-14.65%
Revenue growth 3Y9.24%
Revenue growth 5Y1.54%
Sales Q2Q%-29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-98.08%
EBIT growth 3YN/A
EBIT growth 5Y7.87%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-90.51%
FCF growth 3Y56.1%
FCF growth 5Y4.6%
OCF growth 1Y-86.42%
OCF growth 3Y15.97%
OCF growth 5Y-10.48%